drugset / Trial / NCT01415921
Safety Study of Pyridostigmine in Heart Failure
Phase 2
Completed
33 enrolled
NYU Langone Health
Nathan Kline Institute for Psychiatric Research · collabNational Heart, Lung, and Blood Institute (NHLBI) · collabOklahoma State University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Heart failure, a common heart disease affecting nearly 6 million Americans, is associated with high rates of hospitalization and death. Abnormalities in the autonomic nervous system are thought to play an important role in the progression of heart failure. This proposal aims to determine whether novel application of pyridostigmine, a drug currently approved by the FDA only for the treatment of neuromuscular disease, can improve autonomic nervous system function in heart failure patients.
Timeline
- Start
- 2011-10
- Primary completion
- 2015-07
- Completion
- 2015-07
Publications
- Background Androne AS, Hryniewicz K, Goldsmith R, Arwady A, Katz SD. Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure. Heart. 2003 Aug;89(8):854-8. doi: 10.1136/heart.89.8.854.
- Goldberg R, Norcliffe-Kaufmann L, Kaufmann H, Jeschke-Lopez I, Guo Y, Zhong J, Berger KI, Goldring RM, Goldstein DS, Pope C, Maxwell L, Bharadwaj M, Reyentovich A, Katz SD. Pharmacodynamics, Safety, and Tolerability of Pyridostigmine Bromide in Heart Failure. Curr Ther Res Clin Exp. 2025 Oct 31;103:100814. doi: 10.1016/j.curtheres.2025.100814. eCollection 2025.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyridostigmine | Small molecule | 60 mg | — |